Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.22 is 11% below its 5-year average of -2.91, near the low end of its 5-year range (-5.20–2.34).
142.11% below its 12-month average of -1.33.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.45.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 24 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:02:19.470Z. Historical observations retain their original dates. Historical series through 2026-05-14.
EARNINGS PER SHARE (EPS)
-3.22
EARNINGS PER SHARE (EPS) AVG TTM
-1.33
EARNINGS PER SHARE (EPS) AVG 3Y
-3.00
EARNINGS PER SHARE (EPS) AVG 5Y
-2.91
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-142.11%
CURRENT VS 3Y AVG
-7.24%
CURRENT VS 5Y AVG
-10.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Keros Therapeutics, Inc.
Market Cap
$222.16M
Earnings Per Share (EPS)
-3.22
TTM Avg
-1.33
3Y Avg
-3.00
5Y Avg
-2.91
Market Cap
$222.63M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.25
3Y Avg
-1.31
5Y Avg
-1.33
Market Cap
$228.56M
Earnings Per Share (EPS)
-3.17
TTM Avg
-5.64
3Y Avg
-13.77
5Y Avg
-18.37
Market Cap
$214.92M
Earnings Per Share (EPS)
-0.79
TTM Avg
-1.48
3Y Avg
-1.81
5Y Avg
-1.82
Market Cap
$229.66M
Earnings Per Share (EPS)
-2.38
TTM Avg
-2.11
3Y Avg
-1.81
5Y Avg
-1.81
Market Cap
$229.78M
Earnings Per Share (EPS)
-0.22
TTM Avg
-1.13
3Y Avg
-1.09
5Y Avg
-1.70
Market Cap
$213.92M
Earnings Per Share (EPS)
-11.77
TTM Avg
-8.68
3Y Avg
-4.76
5Y Avg
-3.49
Market Cap
$213.66M
Earnings Per Share (EPS)
0.19
TTM Avg
0.17
3Y Avg
0.00
5Y Avg
-0.12
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $222.16M | -3.22 | -1.33 | -3.00 | -2.91 |
| Profound Medical Corp. (PROF)vs › | $222.63M | -0.99 | -1.25 | -1.31 | -1.33 |
| Vogenx Inc. (VOGX)vs › | $225.48M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $228.56M | -3.17 | -5.64 | -13.77 | -18.37 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.92M | -0.79 | -1.48 | -1.81 | -1.82 |
| BioAge Labs Inc. (BIOA)vs › | $229.66M | -2.38 | -2.11 | -1.81 | -1.81 |
| MacroGenics, Inc. (MGNX)vs › | $229.78M | -0.22 | -1.13 | -1.09 | -1.70 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.92M | -11.77 | -8.68 | -4.76 | -3.49 |
| Niagen Bioscience Inc (NAGE)vs › | $213.66M | 0.19 | 0.17 | 0.00 | -0.12 |
| InflaRx N.V. (IFRX)vs › | $233.46M | -0.57 | -0.79 | -0.77 | -0.98 |
Trailing EPS (TTM)
$-3.22
Forward EPS (Est.)
$-5.54
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 2.34 |
| 2024-12-31 | -5.00 |
| 2023-12-31 | -5.20 |
| 2022-12-31 | -4.15 |
| 2021-12-31 | -2.52 |
| 2020-12-31 | -2.93 |
| 2019-12-31 | -1.39 |
| 2018-12-31 | -0.15 |
